Corticosteroid-induced low immunoglobulin levels in multiple sclerosis - A confounding factor

Background: Changes in immunoglobulin (Ig) levels may occur in association with various drugs targeting immunity, including those used to treat multiple sclerosis (MS). However, influence of high-dose corticosteroids (CS) is poorly described. Objective: To describe influence of disease-modifying drugs (DMD) and CS on the Ig levels. Methods: Monocentric retrospective study examining changes in Ig levels in relation with CS intake in a series of 304 consecutive MS patients (and 1204 samples) followed or hospitalized for 7 years in a single centre. Ig levels are routinely collected in MS patients followed in our centre. Results: IgG levels were significantly lower in MS patients exposed to CS infusion during the last 24 months. IgG levels were also lower in DMD-treated patients exposed to CS. DMD-specific decrease of IgM levels was confirmed in interaction with CS. Conclusion: Stratification by CS exposure suggested that a decrease in Ig levels occurring during DMD treatment was strongly associated with CS infusion. The strong and persistent effect of CS on Ig levels could be a hidden variable and should be considered in further studies targeting Ig levels.

Automated summary

This study investigates the influence of disease-modifying drugs (DMD) and high-dose corticosteroids (CS) on immunoglobulin (Ig) levels in patients with multiple sclerosis (MS). The results demonstrate that CS infusion is strongly associated with a decrease in Ig levels during DMD treatment, suggesting the need for further studies considering the effect of CS on Ig levels.